TCGA MEL CEP350 Cox PH p of 0.018 survivla cut .16.png (36.36 kB)View fileThis item contains files with download restrictions
IMAGE
TCGA MEL CEP350 Cox PH p of 0.0132 survivla cut 0.3.png (37.34 kB)View fileThis item contains files with download restrictions
IMAGE
TCGA MEL CEP350 Cox PH p of 0.0132 survivla cut 0.45.png (38.43 kB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
8 filesFullscreen
Bioinformatics analysis of CEP350 tumor suppression in human TCGA cutaneous melanoma | Datasets Supporting: Tumor Suppressive Functions of CEP350 in Cutaneous Melanoma Cells
Bioinformatics analysis of CEP350 tumor suppression in human TCGA cutaneous melanoma. Publicly available datasets were downloaded from Genomic Data Commons Data Portal using data from the The Cancer Genome Atlas Program and the International Cancer Genome Consortium Data Portal for statistical analyses using R and Shiny.
Supplementary datasets and other information accompanying manuscript: Tumor Suppressive Functions of CEP350 in Cutaneous Melanoma Cells by Aziz Aiderus, Bin Fang, John M. Koomen and Michael B. Mann.
Abstract: We previously identified Cep350 as a novel melanoma haploinsufficient melanoma tumor suppressor gene using SB transposon-mediated mutagenesis to drive melanoma progression in Braf(V600E) mutant (SB|Braf) mice functionally demonstrated that the human CEP350 ortholog is a new melanoma tumor-suppressor gene in human cancer cell lines (Mann et al., Nature Genetics, 2015). Further dissection of the latent tumor suppressive functions of CEP350 in cutaneous melanoma cells is essential for understanding its role in melanoma imitation and progression. In this work, we investigated the role of the novel tumor suppressive functions of CEP350 in cutaneous melanoma cells using comparative informatics, molecular oncology, and proteomics approaches to demonstrate that CEP350 acts via altered cytoskeletal dynamics to contribute to BRAF-V600E driven melanoma.